Author: Bella Hayes
New York, New York–(Newsfile Corp. – January 25, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”), of the important March 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Pacira class action, go to https://rosenlegal.com/submit-form/?case_id=33570 or call…
New York, New York–(Newsfile Corp. – January 25, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Symbotic Inc. (NASDAQ: NASDAQ:) between February 8, 2024 and November 26, 2024, both dates inclusive (the “Class Period”), of the important February 3, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Symbotic securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the…
New York, New York–(Newsfile Corp. – January 25, 2025) – WHY: New York, N.Y., January 25, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sun Communities, Inc. (NYSE: NYSE:) between February 28, 2019 and September 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sun Communities securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Sun…
U.Today – Michael Saylor, co-founder of the MicroStrategy behemoth and a renowned believer, has taken to his account on the X social media network (formerly popular as Twitter) to send yet another daily BTC-themed message to his multi-million army of followers. “Create something better,” Saylor tweetsOnce again, Saylor has published an AI-generated image of himself with BTC symbols lavishly spread in the background. This time, Saylor looks like an artist in a studio with drawing easels surrounding him. Each contains a Bitcoin logo drawn in a slightly different style.“Create something ₿etter,” Saylor tweeted, typing the “B” with four vertical strokes,…
New York, New York–(Newsfile Corp. – January 25, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Innovative Industrial Properties , Inc. (NYSE: NYSE:) between February 27, 2024 and December 19, 2024, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than March 18, 2025. SO WHAT: If you purchased IIPR securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees…
New York, New York–(Newsfile Corp. – January 25, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron (NASDAQ:) Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Regeneron class action, go to https://rosenlegal.com/submit-form/?case_id=33630 or…
New York, New York–(Newsfile Corp. – January 25, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Nextracker Inc. (NASDAQ: NXT) between February 1, 2024 and August 1, 2024, both dates inclusive (the “Class Period”), of the important February 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Nextracker common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Nextracker class action, go to https://rosenlegal.com/submit-form/?case_id=32936 or…
New York, New York–(Newsfile Corp. – January 25, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between May 6, 2021 and November 6, 2024, both dates inclusive (the “Class Period”), of the important January 27, 2025 lead plaintiff deadline. SO WHAT: If you purchased Dentsply Sirona common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Dentsply Sirona class action, go…
Radnor, Pennsylvania–(Newsfile Corp. – January 25, 2025) – The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences (NASDAQ:), Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Cassava losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/cassava-sciences-inc-2024?utm_source=PR&utm_medium=link&utm_campaign=sava&mktm=r You can also contact…
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer ‘s BRAFTOVI combination regimen compared to 40% with investigator’s choice of chemotherapy, representing a doubling of the odds of achieving an objective responseBRAFTOVI combination regimen is the first and only targeted therapy approved by the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ERBITUX ®) and mFOLFOX6 (fluorouracil,…
